Meeting
2020 ASCO Virtual Scientific Program
Assessing the effect of immunosuppressive agents for immune-related adverse event management on tumor response.
Authors
Pankti Reid
University of Chicago, Chicago, IL
Pankti Reid , Daniel Olson , Thomas Gajewski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3066)
DOI
10.1200/JCO.2020.38.15_suppl.3066
Abstract #
3066
Poster Bd #
130
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity: A multicenter case series.
First Author: Catriona Harvey
Poster
2022 ASCO Annual Meeting
The impact of pembrolizumab on patients with pre-existing autoimmune diseases.
First Author: Noor Bazerbashi
Poster
2021 ASCO Annual Meeting
Chronic immune checkpoint inhibitor (ICI) pneumonitis in patients (pts) with non-small cell lung cancer (NSCLC).
First Author: Jessica Stuart
Poster
2021 ASCO Annual Meeting
Post-transplant lymphoproliferative disorder in kidney transplant patients: A multicenter report.
First Author: Elise A. Chong